カタオカ　ヒロシ   Kataoka Hiroshi   片岡　浩史    所属   医学部 医学科（東京女子医科大学病院）    職種   講師
論文種別	総説
言語種別	英語
査読の有無	査読なし
表題	Immediate drop of urine osmolality upon tolvaptan initiation predicts impact on renal prognosis in patients with ADPKD
掲載誌名	正式名：Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 略　 称：Nephrol Dial Transplant ISSNコード：14602385/09310509
掲載区分	国外
巻・号・頁	39(6),pp.1008-1015
著者・共著者	Akihisa Taro, Kataoka Hiroshi, Makabe Shiho, Manabe Shun, Yoshida Rie, Ushio Yusuke, Sato Masayo, Yajima Aiji, Hanafusa Norio, Tsuchiya Ken, Nitta Kosaku, Hoshino Junichi, Mochizuki Toshio
担当区分	2nd著者
発行年月	2024/05/31
概要	BACKGROUND:Tolvaptan, a vasopressin V2 receptor antagonist, is used for treating autosomal dominant polycystic kidney disease (ADPKD). We focused on changes in urinary osmolality (U-Osm) after tolvaptan initiation to determine whether they were associated with the therapeutic response to tolvaptan.METHODS:This was a single-centre, prospective, observational cohort study. Seventy-two patients with ADPKD who received tolvaptan were recruited. We analysed the relationship between changes in U-Osm and annual estimated glomerular filtration rate (eGFR) in terms of renal prognostic value using univariable and multivariable linear regression analyses.RESULTS:The mean value of U-Osm immediately before tolvaptan initiation was 351.8 ± 142.2 mOsm/kg H2O, which decreased to 97.6 ± 23.8 mOsm/kg H2O in the evening. The decrease in U-Osm was maintained in the outpatient clinic 1 month later. However, the 1-month values of U-Osm showed higher variability (160.2 ± 83.8 mOsm/kg H2O) than did those in the first evening of tolvaptan administration. Multivariate analysis revealed that the baseline eGFR, baseline urinary protein and U-Osm change in the evening of the day of admission (initial U-Osm drop) were significantly correlated with the subsequent annual change in eGFR.CONCLUSIONS:U-Osm can be measured easily and rapidly, and U-Osm change within a short time after tolvaptan initiation may be a useful index for the renal prognosis in actual clinical practice.
DOI	10.1093/ndt/gfad232
PMID	37935473